+关注
鹿尧ning
暂无个人介绍
IP属地：辽宁
133
关注
3
粉丝
20
主题
0
勋章
主贴
热门
鹿尧ning
2025-03-27
涉及到直销商业模式的落地。
复锐医疗科技2024年业绩公布，“北美”及“直营”或成关键词
鹿尧ning
2025-03-22
一碗大面
鹿尧ning
2024-10-03
对于小资金，没啥踏空，买的就是确定性，复合了，就上，别问价格。
鹿尧ning
2021-05-06
说说你对这篇新闻的看法...
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3563872536052260","uuid":"3563872536052260","gmtCreate":1600778512889,"gmtModify":1697735997411,"name":"鹿尧ning","pinyin":"lyningluyaoning","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":133,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":20,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.03.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.16","exceedPercentage":"93.05%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"辽宁","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":35,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":417859821675152,"gmtCreate":1743058162672,"gmtModify":1743060546046,"author":{"id":"3563872536052260","authorId":"3563872536052260","name":"鹿尧ning","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563872536052260","idStr":"3563872536052260"},"themes":[],"title":"","htmlText":"涉及到直销商业模式的落地。","listText":"涉及到直销商业模式的落地。","text":"涉及到直销商业模式的落地。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/417859821675152","repostId":"2521807474","repostType":2,"repost":{"id":"2521807474","kind":"news","pubTimestamp":1742528127,"share":"https://www.laohu8.com/m/news/2521807474?lang=zh_CN&edition=full","pubTime":"2025-03-21 11:35","market":"hk","language":"zh","title":"复锐医疗科技2024年业绩公布，“北美”及“直营”或成关键词","url":"https://stock-news.laohu8.com/highlight/detail?id=2521807474","media":"生物科技馆","summary":"3月19日，复锐医疗科技有限公司发布了2024年全年业绩。2022年，公司收益同比增长20.5%，其中直销收益占比66%。2023年公司总收入为359.3百万美元，同比仅增长1.4%，增速明显放缓。结合三年年报数据，“北美”和“直营”成为复锐医疗科技业绩表现的关键词。2022年初，公司董事长兼执行董事刘毅曾表示，中国和北美市场是公司的战略重点。凭借先进的技术和全面的服务，复锐医疗科技已为全球数千万消费者提供美丽与健康守护。","content":"<html><body><article><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162645704v206r2dzyfpd2a2\"/><p>3月19日，<a href=\"https://laohu8.com/S/01696\">复锐医疗科技</a>有限公司发布了2024年全年业绩。公司全年收益达349.1百万美元，其中直销收益占比高达87%，成为公司营收的主要驱动力。从区域表现来看，亚太、欧洲、中东及非洲市场分别实现收益116.2百万美元、50.5百万美元和34.6百万美元，较去年同期分别增长6.0%、0.7%和27.1%。然而，北美市场表现不佳，收益为137.4百万美元，同比下降12.4%。</p><p>公司表示，未来将继续加速全球化布局，尤其在中国和泰国市场，计划进一步提升市场渗透率与毛利率，强化品牌竞争力。</p><p><strong>观察复锐医疗近几年的年报表现，可以发现其增长态势呈现波动</strong>。2022年，公司收益同比增长20.5%，其中直销收益占比66%。北美区域表现尤为亮眼，收益达1.437亿美元，同比增长28.2%；亚太和中东及非洲区域分别增长15.1%和18.7%（分别取得收益取得收益9810万美元、3660万美元）。</p><p>2023年公司总收入为359.3百万美元，同比仅增长1.4%，增速明显放缓。其中，直销收益占比提升至78%，北美及亚太区收益分别为156.9百万美元和109.7百万美元，同比增长9.2%和11.8%。</p><p><strong>结合三年年报数据，“北美”和“直营”成为复锐医疗科技业绩表现的关键词</strong>。2022年初，公司董事长兼执行董事刘毅曾表示，中国和北美市场是公司的战略重点。然而，随着北美市场近年来的不景气，公司整体营收增长逐渐放缓。值得注意的是，直销收益占比持续提升，从2022年的66%增长至2024年的87%，表明公司在直营模式上的投入和成效显著。</p><p>今年，公司高层表示未来将着重布局中国和泰国市场，也体现出区域战略的转移，未来其能否通过技术创新和市场拓展实现新一轮增长，将成为行业关注的焦点。</p><p><strong>关于</strong>复锐医疗</p><p>复锐医疗科技是一家专注于美丽健康事业的全球化集团公司，深耕医疗美容行业二十余年，擅长自然能量源领域的技术研发与应用。</p><p>公司致力于为客户提供医疗美容治疗及相关临床适应症的解决方案，业务涵盖脱毛、嫩肤、暗疮及其疤痕修复、身体与面部塑形、色斑与靓肤、脂肪移植、皮下注射填充剂、皮肤组织重塑注射填充剂、个人护理及美容牙科等多个领域。凭借先进的技术和全面的服务，复锐医疗科技已为全球数千万消费者提供美丽与健康守护。</p><p>素材来源官方媒体/网络新闻</p><p><strong>近期峰会活</strong><strong>动</strong></p><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162646822v206zzt64vdwid4\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162649010v206zv0g95bv0th\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162650544v206z06sn32vjrp\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162657311v206u7molyczj6q\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162658943v206zzoremfpvks\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162701061v2066scyltopfrb\"/></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复锐医疗科技2024年业绩公布，“北美”及“直营”或成关键词</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复锐医疗科技2024年业绩公布，“北美”及“直营”或成关键词\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-21 11:35 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321162703a69ea037&s=b><strong>生物科技馆</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月19日，复锐医疗科技有限公司发布了2024年全年业绩。公司全年收益达349.1百万美元，其中直销收益占比高达87%，成为公司营收的主要驱动力。从区域表现来看，亚太、欧洲、中东及非洲市场分别实现收益116.2百万美元、50.5百万美元和34.6百万美元，较去年同期分别增长6.0%、0.7%和27.1%。然而，北美市场表现不佳，收益为137.4百万美元，同比下降12.4%。公司表示，未来将继续加速...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321162703a69ea037&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1100":"医疗保健设备","01696":"复锐医疗科技","BK1593":"医美概念股","BK1585":"昨日强势股"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321162703a69ea037&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2521807474","content_text":"3月19日，复锐医疗科技有限公司发布了2024年全年业绩。公司全年收益达349.1百万美元，其中直销收益占比高达87%，成为公司营收的主要驱动力。从区域表现来看，亚太、欧洲、中东及非洲市场分别实现收益116.2百万美元、50.5百万美元和34.6百万美元，较去年同期分别增长6.0%、0.7%和27.1%。然而，北美市场表现不佳，收益为137.4百万美元，同比下降12.4%。公司表示，未来将继续加速全球化布局，尤其在中国和泰国市场，计划进一步提升市场渗透率与毛利率，强化品牌竞争力。观察复锐医疗近几年的年报表现，可以发现其增长态势呈现波动。2022年，公司收益同比增长20.5%，其中直销收益占比66%。北美区域表现尤为亮眼，收益达1.437亿美元，同比增长28.2%；亚太和中东及非洲区域分别增长15.1%和18.7%（分别取得收益取得收益9810万美元、3660万美元）。2023年公司总收入为359.3百万美元，同比仅增长1.4%，增速明显放缓。其中，直销收益占比提升至78%，北美及亚太区收益分别为156.9百万美元和109.7百万美元，同比增长9.2%和11.8%。结合三年年报数据，“北美”和“直营”成为复锐医疗科技业绩表现的关键词。2022年初，公司董事长兼执行董事刘毅曾表示，中国和北美市场是公司的战略重点。然而，随着北美市场近年来的不景气，公司整体营收增长逐渐放缓。值得注意的是，直销收益占比持续提升，从2022年的66%增长至2024年的87%，表明公司在直营模式上的投入和成效显著。今年，公司高层表示未来将着重布局中国和泰国市场，也体现出区域战略的转移，未来其能否通过技术创新和市场拓展实现新一轮增长，将成为行业关注的焦点。关于复锐医疗复锐医疗科技是一家专注于美丽健康事业的全球化集团公司，深耕医疗美容行业二十余年，擅长自然能量源领域的技术研发与应用。公司致力于为客户提供医疗美容治疗及相关临床适应症的解决方案，业务涵盖脱毛、嫩肤、暗疮及其疤痕修复、身体与面部塑形、色斑与靓肤、脂肪移植、皮下注射填充剂、皮肤组织重塑注射填充剂、个人护理及美容牙科等多个领域。凭借先进的技术和全面的服务，复锐医疗科技已为全球数千万消费者提供美丽与健康守护。素材来源官方媒体/网络新闻近期峰会活动","news_type":1,"symbols_score_info":{"01696":1}},"isVote":1,"tweetType":1,"viewCount":733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":416140033642872,"gmtCreate":1742605100492,"gmtModify":1742607443519,"author":{"id":"3563872536052260","authorId":"3563872536052260","name":"鹿尧ning","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563872536052260","idStr":"3563872536052260"},"themes":[],"title":"","htmlText":"一碗大面","listText":"一碗大面","text":"一碗大面","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/416140033642872","isVote":1,"tweetType":1,"viewCount":1097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":355960836919368,"gmtCreate":1727913966859,"gmtModify":1727914073519,"author":{"id":"3563872536052260","authorId":"3563872536052260","name":"鹿尧ning","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563872536052260","idStr":"3563872536052260"},"themes":[],"title":"","htmlText":"对于小资金，没啥踏空，买的就是确定性，复合了，就上，别问价格。","listText":"对于小资金，没啥踏空，买的就是确定性，复合了，就上，别问价格。","text":"对于小资金，没啥踏空，买的就是确定性，复合了，就上，别问价格。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355960836919368","isVote":1,"tweetType":1,"viewCount":1856,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":105657331,"gmtCreate":1620300988923,"gmtModify":1620300988923,"author":{"id":"3563872536052260","authorId":"3563872536052260","name":"鹿尧ning","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3563872536052260","idStr":"3563872536052260"},"themes":[],"title":"","htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/105657331","repostId":"2132512485","repostType":4,"isVote":1,"tweetType":1,"viewCount":3303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":417859821675152,"gmtCreate":1743058162672,"gmtModify":1743060546046,"author":{"id":"3563872536052260","authorId":"3563872536052260","name":"鹿尧ning","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563872536052260","authorIdStr":"3563872536052260"},"themes":[],"title":"","htmlText":"涉及到直销商业模式的落地。","listText":"涉及到直销商业模式的落地。","text":"涉及到直销商业模式的落地。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/417859821675152","repostId":"2521807474","repostType":2,"repost":{"id":"2521807474","kind":"news","pubTimestamp":1742528127,"share":"https://www.laohu8.com/m/news/2521807474?lang=zh_CN&edition=full","pubTime":"2025-03-21 11:35","market":"hk","language":"zh","title":"复锐医疗科技2024年业绩公布，“北美”及“直营”或成关键词","url":"https://stock-news.laohu8.com/highlight/detail?id=2521807474","media":"生物科技馆","summary":"3月19日，复锐医疗科技有限公司发布了2024年全年业绩。2022年，公司收益同比增长20.5%，其中直销收益占比66%。2023年公司总收入为359.3百万美元，同比仅增长1.4%，增速明显放缓。结合三年年报数据，“北美”和“直营”成为复锐医疗科技业绩表现的关键词。2022年初，公司董事长兼执行董事刘毅曾表示，中国和北美市场是公司的战略重点。凭借先进的技术和全面的服务，复锐医疗科技已为全球数千万消费者提供美丽与健康守护。","content":"<html><body><article><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162645704v206r2dzyfpd2a2\"/><p>3月19日，<a href=\"https://laohu8.com/S/01696\">复锐医疗科技</a>有限公司发布了2024年全年业绩。公司全年收益达349.1百万美元，其中直销收益占比高达87%，成为公司营收的主要驱动力。从区域表现来看，亚太、欧洲、中东及非洲市场分别实现收益116.2百万美元、50.5百万美元和34.6百万美元，较去年同期分别增长6.0%、0.7%和27.1%。然而，北美市场表现不佳，收益为137.4百万美元，同比下降12.4%。</p><p>公司表示，未来将继续加速全球化布局，尤其在中国和泰国市场，计划进一步提升市场渗透率与毛利率，强化品牌竞争力。</p><p><strong>观察复锐医疗近几年的年报表现，可以发现其增长态势呈现波动</strong>。2022年，公司收益同比增长20.5%，其中直销收益占比66%。北美区域表现尤为亮眼，收益达1.437亿美元，同比增长28.2%；亚太和中东及非洲区域分别增长15.1%和18.7%（分别取得收益取得收益9810万美元、3660万美元）。</p><p>2023年公司总收入为359.3百万美元，同比仅增长1.4%，增速明显放缓。其中，直销收益占比提升至78%，北美及亚太区收益分别为156.9百万美元和109.7百万美元，同比增长9.2%和11.8%。</p><p><strong>结合三年年报数据，“北美”和“直营”成为复锐医疗科技业绩表现的关键词</strong>。2022年初，公司董事长兼执行董事刘毅曾表示，中国和北美市场是公司的战略重点。然而，随着北美市场近年来的不景气，公司整体营收增长逐渐放缓。值得注意的是，直销收益占比持续提升，从2022年的66%增长至2024年的87%，表明公司在直营模式上的投入和成效显著。</p><p>今年，公司高层表示未来将着重布局中国和泰国市场，也体现出区域战略的转移，未来其能否通过技术创新和市场拓展实现新一轮增长，将成为行业关注的焦点。</p><p><strong>关于</strong>复锐医疗</p><p>复锐医疗科技是一家专注于美丽健康事业的全球化集团公司，深耕医疗美容行业二十余年，擅长自然能量源领域的技术研发与应用。</p><p>公司致力于为客户提供医疗美容治疗及相关临床适应症的解决方案，业务涵盖脱毛、嫩肤、暗疮及其疤痕修复、身体与面部塑形、色斑与靓肤、脂肪移植、皮下注射填充剂、皮肤组织重塑注射填充剂、个人护理及美容牙科等多个领域。凭借先进的技术和全面的服务，复锐医疗科技已为全球数千万消费者提供美丽与健康守护。</p><p>素材来源官方媒体/网络新闻</p><p><strong>近期峰会活</strong><strong>动</strong></p><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162646822v206zzt64vdwid4\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162649010v206zv0g95bv0th\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162650544v206z06sn32vjrp\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162657311v206u7molyczj6q\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162658943v206zzoremfpvks\"/><img src=\"https://fid-75186.picgzc.qpic.cn/20250321162701061v2066scyltopfrb\"/></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复锐医疗科技2024年业绩公布，“北美”及“直营”或成关键词</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复锐医疗科技2024年业绩公布，“北美”及“直营”或成关键词\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-21 11:35 北京时间 <a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321162703a69ea037&s=b><strong>生物科技馆</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月19日，复锐医疗科技有限公司发布了2024年全年业绩。公司全年收益达349.1百万美元，其中直销收益占比高达87%，成为公司营收的主要驱动力。从区域表现来看，亚太、欧洲、中东及非洲市场分别实现收益116.2百万美元、50.5百万美元和34.6百万美元，较去年同期分别增长6.0%、0.7%和27.1%。然而，北美市场表现不佳，收益为137.4百万美元，同比下降12.4%。公司表示，未来将继续加速...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321162703a69ea037&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1100":"医疗保健设备","01696":"复锐医疗科技","BK1593":"医美概念股","BK1585":"昨日强势股"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250321162703a69ea037&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2521807474","content_text":"3月19日，复锐医疗科技有限公司发布了2024年全年业绩。公司全年收益达349.1百万美元，其中直销收益占比高达87%，成为公司营收的主要驱动力。从区域表现来看，亚太、欧洲、中东及非洲市场分别实现收益116.2百万美元、50.5百万美元和34.6百万美元，较去年同期分别增长6.0%、0.7%和27.1%。然而，北美市场表现不佳，收益为137.4百万美元，同比下降12.4%。公司表示，未来将继续加速全球化布局，尤其在中国和泰国市场，计划进一步提升市场渗透率与毛利率，强化品牌竞争力。观察复锐医疗近几年的年报表现，可以发现其增长态势呈现波动。2022年，公司收益同比增长20.5%，其中直销收益占比66%。北美区域表现尤为亮眼，收益达1.437亿美元，同比增长28.2%；亚太和中东及非洲区域分别增长15.1%和18.7%（分别取得收益取得收益9810万美元、3660万美元）。2023年公司总收入为359.3百万美元，同比仅增长1.4%，增速明显放缓。其中，直销收益占比提升至78%，北美及亚太区收益分别为156.9百万美元和109.7百万美元，同比增长9.2%和11.8%。结合三年年报数据，“北美”和“直营”成为复锐医疗科技业绩表现的关键词。2022年初，公司董事长兼执行董事刘毅曾表示，中国和北美市场是公司的战略重点。然而，随着北美市场近年来的不景气，公司整体营收增长逐渐放缓。值得注意的是，直销收益占比持续提升，从2022年的66%增长至2024年的87%，表明公司在直营模式上的投入和成效显著。今年，公司高层表示未来将着重布局中国和泰国市场，也体现出区域战略的转移，未来其能否通过技术创新和市场拓展实现新一轮增长，将成为行业关注的焦点。关于复锐医疗复锐医疗科技是一家专注于美丽健康事业的全球化集团公司，深耕医疗美容行业二十余年，擅长自然能量源领域的技术研发与应用。公司致力于为客户提供医疗美容治疗及相关临床适应症的解决方案，业务涵盖脱毛、嫩肤、暗疮及其疤痕修复、身体与面部塑形、色斑与靓肤、脂肪移植、皮下注射填充剂、皮肤组织重塑注射填充剂、个人护理及美容牙科等多个领域。凭借先进的技术和全面的服务，复锐医疗科技已为全球数千万消费者提供美丽与健康守护。素材来源官方媒体/网络新闻近期峰会活动","news_type":1,"symbols_score_info":{"01696":1}},"isVote":1,"tweetType":1,"viewCount":733,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":416140033642872,"gmtCreate":1742605100492,"gmtModify":1742607443519,"author":{"id":"3563872536052260","authorId":"3563872536052260","name":"鹿尧ning","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563872536052260","authorIdStr":"3563872536052260"},"themes":[],"title":"","htmlText":"一碗大面","listText":"一碗大面","text":"一碗大面","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/416140033642872","isVote":1,"tweetType":1,"viewCount":1097,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":355960836919368,"gmtCreate":1727913966859,"gmtModify":1727914073519,"author":{"id":"3563872536052260","authorId":"3563872536052260","name":"鹿尧ning","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563872536052260","authorIdStr":"3563872536052260"},"themes":[],"title":"","htmlText":"对于小资金，没啥踏空，买的就是确定性，复合了，就上，别问价格。","listText":"对于小资金，没啥踏空，买的就是确定性，复合了，就上，别问价格。","text":"对于小资金，没啥踏空，买的就是确定性，复合了，就上，别问价格。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/355960836919368","isVote":1,"tweetType":1,"viewCount":1856,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":105657331,"gmtCreate":1620300988923,"gmtModify":1620300988923,"author":{"id":"3563872536052260","authorId":"3563872536052260","name":"鹿尧ning","avatar":"https://static.tigerbbs.com/33edfb3916c6ee995f0f49410762dd4b","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3563872536052260","authorIdStr":"3563872536052260"},"themes":[],"title":"","htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/105657331","repostId":"2132512485","repostType":4,"isVote":1,"tweetType":1,"viewCount":3303,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
